Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Metastatic prostate cancer remains incurable, highlighting the urgent need for novel therapeutic strategies.
• Cancer metastasis is driven by specific genes that, when altered in non-metastatic tissue, initiate a cascade of downstream gene activation.
• Identifying these metastasis-driving genes is crucial for developing targeted therapies to manage advanced prostate cancer.

Purpose of the Study:

• To outline a strategy for identifying metastasis-driving genes in prostate cancer.
• To explore the potential of these genes as therapeutic targets for metastatic disease.
• To discuss the challenges and requirements for effective identification of these critical genes.

Main Methods:

• Comparative analysis of gene expression profiles from patient-derived metastatic and non-metastatic prostate cancer tissues.
• Utilizing xenografts from patient prostate cancers developed via subrenal capsule grafting for tissue acquisition.
• Functional validation by silencing candidate genes to assess inhibition of metastatic properties.

Main Results:

• The study proposes a methodology for pinpointing genes with altered expression in metastatic prostate cancer.
• It emphasizes the need for clinically relevant tissue models, such as patient-derived xenografts.
• Challenges in identifying master regulatory genes using current methodologies are acknowledged.

Conclusions:

• Identifying metastasis-driving genes offers a promising avenue for developing targeted therapies against prostate cancer metastasis.
• The proposed comparative gene expression analysis, coupled with functional validation, can uncover key regulatory genes.
• Overcoming challenges related to tissue acquisition and gene identification methodology is essential for advancing this research.